drugset

drugset / Trial / NCT05393466

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05393466 ↗

Phase 1/2 Not yet recruiting 30 enrolled Xcovery Holdings, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a three-stage study, consisting of Phase Ia dose-escalation, Phase Ib dose expansion, and a Phase II component.

Timeline

Start: 2026-07-01
Primary completion: 2028-01-30
Completion: 2029-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BPI-361175	Unknown	—	Oral

Indications